PHARMACEUTICALS
Untitled Page
Irvine's Spectrum Pharmaceuticals gets FDA nod for cancer therapy
Zevalin expansion approved for follicular Non-Hodgkin's lymphoma.
By Kristen SchottPublished: September 08, 2009 11:09 AM
Irvine-based Spectrum Pharmaceuticals recently received approval from the U.S. Food and Drug Administration for the expansion of its Zevalin product in the treatment of follicular Non-Hodgkin's lymphoma.
The larger label increases the drug's reach to 43,000 patients a year and will be used as part of a therapy for previously untreated follicular occurrences of the disease, which are the most common forms, according to the National Cancer Institute. It will be used in patients who achieve a partial or complete response to first-line chemotherapy – or the primary stage of treatment.
The new addition coincides with the 2002 FDA approval of Zevalin as a treatment for patients with relapsed or refractory, low-grade or follicular B-cell Non-Hodgkin's lymphoma.
NEXT PAGE >>
Related headlines
Orange's St. Joseph Hospital debuts revolutionary procedure
'OC METRO Minute,' Sept. 3: Visiogen set to be acquired by Abbot for $400 million
O.C. Affiliate of Susan G. Komen for the Cure launches Race Registration Suite
|
||||
|
The larger label increases the drug's reach to 43,000 patients a year and will be used as part of a therapy for previously untreated follicular occurrences of the disease, which are the most common forms, according to the National Cancer Institute. It will be used in patients who achieve a partial or complete response to first-line chemotherapy – or the primary stage of treatment. The new addition coincides with the 2002 FDA approval of Zevalin as a treatment for patients with relapsed or refractory, low-grade or follicular B-cell Non-Hodgkin's lymphoma. NEXT PAGE >> Related headlines Orange's St. Joseph Hospital debuts revolutionary procedure 'OC METRO Minute,' Sept. 3: Visiogen set to be acquired by Abbot for $400 million O.C. Affiliate of Susan G. Komen for the Cure launches Race Registration Suite |
||||
